APP and Alzheimer disease: Most studies rely on transgenic models such as APP/PS1, which do not recapitulate environmental exposures or genetic heterogeneity in sporadic AD, and there is limited evaluation of blood–brain barrier penetration or cognitive benefit for ferroptosis inhibitors such as CuII(atsm).